The investment will be developed in three different Actions:
a) RESEARCH and DEVELOPMENT of new super-generic pharmaceutical forms that, in combination with a specialised device, will achieve the successful administration of the drug. Development of new value added pharmaceutical products in categories of great international interest, aimed at the treatment of acute and chronic diseases of the respiratory system
b) in the construction of the factory which will constitute a new facility for the production of products of high innovation and high added value, not produced by the company until now,
c) and in the construction of a new state-of-the-art Experimental Laboratory for Experimental - Applied Biomedical Research and Education. The company's new factory will be built in the Industrial Park of Keratea (Action b), while the company's new Experimental laboratory will be designed and built in Spata (Action c).
